NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis $146.80 +0.70 (+0.48%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$144.35▼$148.0250-Day Range$130.86▼$147.4652-Week Range$99.36▼$150.39Volume744,756 shsAverage Volume808,833 shsMarket Capitalization$14.77 billionP/E Ratio40.44Dividend YieldN/APrice Target$154.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Neurocrine Biosciences alerts: Email Address Neurocrine Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside5.0% Upside$154.08 Price TargetShort InterestHealthy2.61% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.84Based on 17 Articles This WeekInsider TradingSelling Shares$11.01 M Sold Last QuarterProj. Earnings Growth59.48%From $4.22 to $6.73 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.70 out of 5 starsMedical Sector65th out of 936 stocksBiological Products, Except Diagnostic Industry7th out of 154 stocks 2.4 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 16 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.61% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently decreased by 6.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 3.2 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Neurocrine Biosciences this week, compared to 9 articles on an average week.Search InterestOnly 6 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows11 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,009,150.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 59.48% in the coming year, from $4.22 to $6.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 40.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 40.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 6.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Neurocrine Biosciences Stock (NASDAQ:NBIX)Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More NBIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBIX Stock News HeadlinesJuly 19, 2024 | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Julie Cooke Sells 900 SharesJuly 3, 2024 | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Julie Cooke Sells 10,000 SharesJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 25 at 8:28 AM | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Given "Hold" Rating at Needham & Company LLCJuly 21, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Upgraded to "Strong-Buy" at StockNews.comJuly 20, 2024 | americanbankingnews.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 930 Shares of StockJuly 20, 2024 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $135,036.00 in StockJuly 19, 2024 | markets.businessinsider.comNeurocrine Biosciences Launches INGREZZA SPRINKLE Capsules - Quick FactsJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 18, 2024 | prnewswire.comNeurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty SwallowingJuly 11, 2024 | prnewswire.comNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial ResultsJuly 11, 2024 | seekingalpha.comNeurocrine Biosciences: Diverse Pipeline, High Margins, And Growth Potential In BiotechJuly 9, 2024 | seekingalpha.comNeurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term GrowthJuly 1, 2024 | prnewswire.comNeurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAHJune 17, 2024 | investorplace.com7 Breakthrough Biotech Stocks for a Shot of Portfolio AdrenalineJune 3, 2024 | prnewswire.comNeurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024June 3, 2024 | prnewswire.comNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineJune 3, 2024 | prnewswire.comNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineSee More Headlines Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,400Year FoundedN/APrice Target and Rating Average Stock Price Target$154.08 High Stock Price Target$216.00 Low Stock Price Target$100.00 Potential Upside/Downside+5.0%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$3.63 Trailing P/E Ratio40.44 Forward P/E Ratio34.79 P/E GrowthN/ANet Income$249.70 million Net Margins18.65% Pretax Margin23.71% Return on Equity17.45% Return on Assets12.14% Debt Debt-to-Equity RatioN/A Current Ratio2.52 Quick Ratio2.47 Sales & Book Value Annual Sales$1.89 billion Price / Sales7.83 Cash Flow$2.60 per share Price / Cash Flow56.56 Book Value$22.72 per share Price / Book6.46Miscellaneous Outstanding Shares100,640,000Free Float96,310,000Market Cap$14.77 billion OptionableOptionable Beta0.37 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Kevin C. Gorman Ph.D. (Age 66)CEO & Director Comp: $2.05MMr. Matthew C. Abernethy (Age 44)Chief Financial Officer Comp: $1.06MDr. Jude Onyia Ph.D. (Age 60)Chief Scientific Officer Comp: $1.22MMr. Kyle W. Gano Ph.D. (Age 51)Chief Business Development & Strategy Officer Comp: $990.12kDr. Eiry Wyn Roberts M.D. (Age 60)Chief Medical Officer Comp: $1.12MJane SorensenHead of Investor RelationsMr. Darin M. Lippoldt Esq. (Age 58)Chief Legal Officer & Corporate Secretary Comp: $921.01kMs. Julie S. Cooke (Age 58)Chief Human Resources Officer Mr. Eric S. Benevich (Age 59)Chief Commercial Officer Comp: $805kMr. David Warren Boyer (Age 44)Chief Corporate Affairs Officer More ExecutivesKey CompetitorsBio-TechneNASDAQ:TECHAcceleron PharmaNASDAQ:XLRNQiagenNYSE:QGENMomenta PharmaceuticalsNASDAQ:MNTACRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 13,069 shares on 7/26/2024Ownership: 0.928%EFG Asset Management North America Corp.Sold 2,764 shares on 7/26/2024Ownership: 0.033%State of Michigan Retirement SystemSold 200 shares on 7/26/2024Ownership: 0.024%Bristlecone Advisors LLCSold 95 shares on 7/26/2024Ownership: 0.003%Patriot Financial Group Insurance Agency LLCSold 70 shares on 7/26/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions NBIX Stock Analysis - Frequently Asked Questions How have NBIX shares performed this year? Neurocrine Biosciences' stock was trading at $131.76 on January 1st, 2024. Since then, NBIX stock has increased by 11.4% and is now trading at $146.80. View the best growth stocks for 2024 here. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings data on Wednesday, May, 1st. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.04 by $0.62. The business had revenue of $515.30 million for the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 17.45% and a net margin of 18.65%. What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' top institutional investors include Bank of New York Mellon Corp (0.93%), Allspring Global Investments Holdings LLC (0.71%), Assenagon Asset Management S.A. (0.25%) and Sumitomo Mitsui Trust Holdings Inc. (0.24%). Insiders that own company stock include Neurocrine Biosciences Inc, Kevin Charles Gorman, Kyle Gano, Gary A Lyons, William H Rastetter, Eric Benevich, Darin Lippoldt, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Eiry Roberts, Malcolm Lloyd-Smith, Julie Cooke, Jude Onyia, Ingrid Delaet, David W Boyer, Shalini Sharp, Leslie V Norwalk, George J Morrow and Dimitri E Grigoriadis. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV) and Walt Disney (DIS). This page (NASDAQ:NBIX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBIX Stock Alerts